Skip to main content
Clinical Trials/CTRI/2024/10/074939
CTRI/2024/10/074939
Not yet recruiting
Phase 3

Nasal high frequency oscillation ventilation versus Nasal continuous positive airway pressure as primary respiratory support in preterm neonates of more than 30weeks gestation with Respiratory distress syndrome: an Open labelled Randomized controlled trial

Padamata Likhitha1 site in 1 country124 target enrollmentStarted: October 10, 2024Last updated:

Overview

Phase
Phase 3
Status
Not yet recruiting
Sponsor
Padamata Likhitha
Enrollment
124
Locations
1
Primary Endpoint
Treatment failure Defined as requirement of an use of an alternative NRS modality NIPPV or BiPAP,

Overview

Brief Summary

This study will be conducted in a level 3 NICU in neonates born more than 30 weeks gestation, meeting the inclusion criteria. After attaining the consent, the neonate will be enrolled, assigned to respective groups after stratified randomization. Baseline characteristics will be recorded at enrolment. Treatment failure and need for IMV at 72 HOL will be observed as primary outcome.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
None

Eligibility Criteria

Ages
0.00 Day(s) to 30.00 Day(s) (—)
Sex
All

Inclusion Criteria

  • preterm neonates of gestational age 30-36+6/7 weeks diagnosed with respiratory distress syndrome.

Exclusion Criteria

  • neonates who had undergone endotracheal intubation or had received surfactant prior to randomization , neonates with gross congenital anomalies whose caretakers refuse to give consent to participate in study.

Outcomes

Primary Outcomes

Treatment failure Defined as requirement of an use of an alternative NRS modality NIPPV or BiPAP,

Time Frame: Treatment failure Defined as requirement of an use of an alternative NRS modality NIPPV or BiPAP, | Requirement of IMV within 72 hours of postnatal age

Requirement of IMV within 72 hours of postnatal age

Time Frame: Treatment failure Defined as requirement of an use of an alternative NRS modality NIPPV or BiPAP, | Requirement of IMV within 72 hours of postnatal age

Secondary Outcomes

  • Requirement of surfactant replacement therapy, Pneumothorax, Mortality or BPD (defined as oxygen requirement at 28 days of postnatal age), Mortality, BPD (defined as oxygen requirement at 28 days of postnatal age), Duration of NRS support, Duration of IMV support, Duration of both NRS and IMV support, Duration of hospital stay, Severe intraventricular hemorrhage, Necrotizing enterocolitis stage 2 or more as per modified Bell’s staging, Retinopathy of prematurity (ROP) requiring intervention, Nasal injury(respiratory support started within 6hours)

Investigators

Sponsor
Padamata Likhitha
Sponsor Class
Private hospital/clinic
Responsible Party
Principal Investigator
Principal Investigator

Padamata Likhitha

Ankura hospital for women and children

Study Sites (1)

Loading locations...

Similar Trials